
Rocket Doctor's Virtually-Enabled Emergency Department Diversion Program Reduces Strain on Overwhelmed Hospitals
The Ontario program has saved an estimated $1.4 million by diverting 3,065 patients from the ER between June 2022 and December 2024. This is based on an average of $475 per visit, using cost data from Scarborough Health Network and Canadian Institute for Health Information .
In the last 3 months across Alberta, Rocket Doctor has facilitated 12,000+ patient visits with MDs, with 98% of cases resolved virtually and <1% sent to ED.
The Rocket Doctor platform combines smart patient-provider matching, branded hospital intake pages, and flexible staffing models to support hospital partners
Vancouver, BC, July 31, 2025 (GLOBE NEWSWIRE) — Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') and its wholly owned digital health platform and marketplace, Rocket Doctor, are providing a scalable response to Canada's emergency department crisis with a data-backed diversion program. The program uses smart triage, provider infrastructure, and AI-enabled care to safely keep appropriate patients with low-acuity healthcare concerns out of overcrowded hospitals, while getting them the comprehensive out-patient care that they need, faster.
Across Canada, hospitals are facing unprecedented strain. Since 2019, emergency departments have experienced more than 1.14 million hours of closure , the equivalent of 47,500 lost days of emergency care. Ontario and Alberta have been hit especially hard, with rural ER closures and care disruptions becoming a regular occurrence. This reality has left communities with few options and patients in critical need of safe, timely alternatives.
British Columbia is equally seeing regular ER closures throughout 2025, causing challenges for patients, healthcare systems and especially rural communities: BC is not Alone – Rural ER Crisis across Canada – BC Rural Health Network
While in many cases a virtual-only system is not a replacement for in-person emergency care, Rocket Doctor's ED diversion program is helping to support hospitals and patients to fill a void in accessible care. The platform enables hospital systems to allow patients to self-select to reroute themselves to clinically appropriate, out-patient consultations, leveraging customized intake forms, real-time triage, and a flexible physician network, either from independent MDs on Rocket Doctor's platform, or the hospital's own staff.
At Georgian Bay General Hospital in Ontario, the results speak for themselves. Between June 2022 and December 2024, more than 3,065 patients have been successfully managed through MDs on Rocket Doctor's platform, with 97% of patients treated virtually and only 1% redirected to the ER. Patients waited an average of just 20 minutes to connect with a physician. The estimated system savings totaled $1.4 million, based on an average $475 cost per diverted ER visit multiplied by the total number of patients seen. All visits were covered under OHIP, with no additional fees to patients.
In Alberta, Rocket Doctor has seen similar success across its broader platform, with over 12,000 patients seen in the past 3 months alone, entirely funded by provincial health insurance. More than 98% of these visits were resolved without requiring in-person care, and less than 1% were sent to the ER.
'We see so many patients in our rural, remote and even urban communities going to ED, often when they recognize that they could be seen outside the hospital.' Said Dr. William Cherniak, CEO of Rocket Doctor. 'There has been a lot of good content from the Canadian Association of Emergency Physicians (CAEP) to recognize that we need to support patients to access healthcare where they see most appropriate. We often see patients choose an ED with low-acuity issues simply because of a lack of access to family doctors, or other accessible out-patient choices.'
By leveraging smart triage and other digital tools, Rocket Doctor's ED Diversion Program and broader platform pairs patients with the right physician based on their needs, empowering physicians to order labs, imaging, make specialist referrals, or escalate care to in-person options when clinically necessary (although rare). Patients can also rebook with the same physician to ensure continuity of care, improving outcomes and reducing unnecessary visits.
'We are filling that gap by empowering physicians in a team-based cloud-enabled model of care with technological support to work at the top of their license within their clinical competencies digitally.' said Dr. Cherniak. 'We're building a system that gives patients a smarter entry point and gives physicians the tools to work independently, safely, and efficiently.'
As staffing shortages and rural hospital disruptions continue to affect patients across Canada, Rocket Doctor and Treatment.com AI are offering hospitals and provincial systems a deployable, proven solution; one that reduces backlog, lowers system strain, and drives meaningful outcomes at scale.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine – the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at www.treatment.com or contact [email protected] .
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status.
To learn more about Rocket Doctor's platform and services, visit www.rocketdoctor.ca (Canada) or www.rocketdoctor.io (U.S.), or contact [email protected] .
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Treatment.com AI
Email: [email protected]
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Dr. Bill Cherniak, CEO, Rocket Doctor
Email: [email protected]
Media inquiries: [email protected]
Cautionary Statement
This news release contains forward-looking statements that are based on Treatment.com AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
AI-Powered Pathogen Detection App: Provisional Patent Filed by FendX CEO
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce that its CEO, Dr. Carolyn Myers, has filed a provisional patent application with the United States Patent and Trademark Office. The application, titled "AI Adaptive App Pathogen Detection Platform" dated June 25, 2025, will be assigned to FendX as part of its expanding portfolio of hygiene-related technologies. The invention described in the patent application is being designed to combine mobile-based imaging, biosensor technology, and artificial intelligence ("AI") to enable real-time detection of pathogens on surfaces using a mobile device such as a smartphone. The aim is to develop a portable, intelligent and user-friendly diagnostic tool for both consumer and professional use. "Traditional diagnostic methods are powerful but often take time to detect and identify pathogens, and they're usually limited to lab settings," said Dr. Carolyn Myers, FendX CEO and inventor. "This invention is part of our ongoing commitment to making surface protection smarter and I believe it shows how mobile devices and AI can work together to bring advanced pathogen detection directly to the user." About FendX Technologies Inc. FendX is a surface protection company leveraging its proprietary technology to develop product solutions that help reduce the spread of harmful pathogens in everyday environments. The Company is advancing an eco-friendly, smart sponge designed to deliver effective cleaning while minimizing environmental impact. This innovative product complements FendX's broader pipeline, which includes REPELWRAP™ film, a protective surface coating with repelling properties that significantly reduce adhesion and transmission of pathogens on high-touch surfaces, and a spray-based coating with similar functionality. Additionally, the Company is developing specialized catheter coatings, with its first coating being for Foley catheters. The Company holds an exclusive supply agreement for the eco-sponge and an exclusive license to certain intellectual property related to the use of the sponge, as well as exclusive worldwide licenses and intellectual property for its coating technologies. ON BEHALF OF THE COMPANY "Carolyn Myers"Carolyn MyersChief Executive Officer and Director Contacts: Dr. Carolyn Myers, CEO and Director1-800-344-9868investor@ For more information, please visit and the Company's profile on SEDAR+ at Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the provisional patent application, invention and goals related to the development of the invention;; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the provisional patent application may not receive regulatory approval; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development of the invention;; risks related to research and development activities for each of the film, spray formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans; risks that the Company's products, including the eco-friendly sponge, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP, including the provisional patent application to be assigned to the Company; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


UPI
a day ago
- UPI
Study shows rising popularity of over-the-counter birth control pill
Two years after U.S. approval of the first over-the-counter birth control pill, new research shows many people who face barriers to care are turning to it. File Photo by Billie Jean Shaw/UPI Two years after U.S. approval of the first over-the-counter birth control pill, new research shows many people who face barriers to medical care are turning to it. The study, published Monday in JAMA Network Open, included data from 986 people ages 15 to 45 across 44 states. All had obtained the pill -- known as Opill -- either online or from a pharmacy. Researchers found many switched from less effective birth control methods or from using no contraception at all. There was a 31.8% increase in use among people who had previously used no birth control, and a 41% increase among those who had relied on methods like condoms or emergency contraception. Opill, made by drug company Perrigo, is a progestin-only pill that can be bought without a prescription. When the U.S. Food and Drug Administration approved it in 2023, it said the move could help lower barriers to access. At that time, the FDA noted that nearly half of the 6.1 million pregnancies in the U.S. each year are unintended, CBS News reported. "This is one of the first studies to show that over-the-counter birth control pills are reaching the very people they're meant to help -- those who face the greatest barriers to care," said lead study author Dr. Maria Rodriguez, a professor of obstetrics and gynecology at Oregon Health & Science University in Portland. The study found that people using the OTC pill were more often uninsured, younger (15 to 20 years of age), and living in rural areas. The top reason people gave for choosing the OTC pill was that it did not require a doctor's appointment. Others said they did not have a regular physician. "At a time when pregnancy is becoming even more dangerous in the United States -- especially for people of color, those with low incomes and those living in rural communities -- our findings underscore that OTC contraception is a powerful tool for reproductive autonomy," Rodriguez said in a news release. An outside expert who reviewed the findings agreed. Dr. Jessica Shepherd is a board-certified OB/GYN and chief medical officer of the online health company Hers. "While greater access to contraception without prescriptions can be life-changing for women with limited resources, it also highlights how deeply the repercussions of unplanned pregnancies still ripple through health care systems and communities," she told CBS News. "Unplanned pregnancies often result in higher maternal and infant health risks, financial strain and long-term socioeconomic challenges-consequences that weigh most heavily on women who already face barriers to care," Shepherd added. More information Learn more about how Opill works. Copyright © 2025 HealthDay. All rights reserved.